I help clients secure robust patent protection for their inventions in the pharmaceutical, chemical, and biotechnology industries.
Leveraging her research experience in organic chemistry, Dr. Laura Wzorek counsels clients on building patent portfolios aligned with their business objectives.
Adept at navigating complex prior art landscapes and timing of filings, Laura develops patent portfolio strategies and prepares and prosecutes U.S. and foreign patent applications focused on small molecule pharmaceuticals, polymorphs, pharmaceutical formulations, therapeutic uses, synthetic methods, platform technologies, and materials science. She also conducts freedom-to-operate and patentability analyses and provides IP diligence support for fundraising and licensing transactions.
Laura's doctoral studies focused on asymmetric organometallic catalysis in the laboratory of Professor James Morken at Boston College.
University of California, Berkeley, B.S., Chemistry, 2006
Bar and Court Admissions
BAR ADMISSIONS
Massachusetts
U.S. Patent & Trademark Office (Agency)
Experience
Patent prosecution counsel for a variety of pharmaceutical companies, universities, and venture-backed research institutions. A list of representative patents obtained and patent applications drafted is shown below:
Small molecule pharmaceuticals:
Heterocyclic Glutaminase Inhibitors (US 10793535)
Substituted Amino Triazoles Useful as Human Chitinase Inhibitors (US 9944624)
Oral Complement Factor D Inhibitors (WO 2021/072198)
Polymorphs:
Crystal Forms of Glutaminase Inhibitors (US 10316030)
Crystalline Salt Forms of BOC-D-Arg-DMT-Lys-(Boc)-Phe-NH2 (US 11034724)
Crystalline Bis- and Tri-Hydrochloride Salt of Elamipretide (US 10676506)
Therapeutic Methods:
Combination Therapy with Gluatminase Inhibitors and Immuno-Oncology Agents (US 10258619)
Genotype-Agnostic Rescue of Cystic Fibrosis with Small Molecule Biocarbonate Channels (WO 2019/075214)
Synthetic Methods:
N-Carboxyanhydride-Based-Scale Synthesis of Elamipretide (US 10961273)
Successfully appealed to the USPTO Patent Trial and Appeal Board (PTAB) an obviousness-type double patenting rejection of claims to a Phase II drug candidate for the treatment of cancer.
Other Publications
Le, H., Kyne, R. E., Brozek, L. A., Morken, J. P., “Catalytic enantioselective allyl-allyl cross-coupling with a borylated allylboronate” Organic Letters 2013, 15, 1432.
Brozek, L. A., Ardolino, M. J., Morken, J. P., "Diastereocontrol in Asymmetric Allyl-Allyl Cross Coupling: Stereocontrolled Reaction of Prochiral Allylboronates with Prochiral Allyl Chlorides," Journal of the American Chemical Society 2011, 133, 16778.
Brozek, L. A., Sieber, J. D., Morken, J. P., "Catalytic Enantioselective Conjugate Allylation of Unsaturated Methylidene Ketones," Organic Letters 2011, 13, 995.
Zhang, P., Brozek, L. A., Morken, J. P., "Enantioselective Pd-Catalyzed Allyl-Allyl Cross Coupling," Journal of the American Chemical Society 2010, 132, 10686. Highlighted as "Synfact of the Month" by the journal Synfacts, November 2010.
Honors & Involvement
HONORS
Best Lawyers: Ones to Watch - Patent Law (2024-2026), Intellectual Property Law (2026), and Life Sciences Practice (2026)
World Intellectual Property Review: WIPR Leaders (2024)
Massachusetts Super Lawyers: 'Rising Star' in Intellectual Property Law (2021-2024)
BPLA Writing Competition – First Place (2019)
Michael Fricklas and Donna Astion Prize in Intellectual Property and Entertainment Law – Boston University School of Law (2019)
LaMattina Fellowship, Boston College
Speaking Engagements
Strategic Insights from Cellect and Allergan: Practice Tips for Maximizing Patent Term and Value, AIPLA Corporate Practice Committee Webinar, June 2026
"Asymmetric Allyl-Allyl Coupling via 3,3′-Reductive Elimination of Allyl-Metal Complexes and Development of Diastereoselective Transformations," Oral presentation at 13th Annual JCF Frühjahrssymposium, Nürnberg, Germany, March 2011
We use cookies to enhance user experience, improve functionality and performance, and for analysis of website traffic. By clicking “accept”, you agree to the use of cookies. For more information about our cookie policy and the information we collect, please review our Privacy Statement.
Foley Hoag
Email Disclaimer
Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK," you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you.
If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Foley Hoag.
